BridgeBio Pharma (NASDAQ:BBIO) CAO Sells $143,160.00 in Stock

Key Points

• Maricel Apuli, BridgeBio's CAO, sold 2,000 shares on April 30 at an average price of $71.58 for proceeds of $143,160, lowering her stake by 1.47% to 134,115 shares (about $9.60M); the sale was made under a pre-arranged Rule 10b5-1 trading plan.
• BridgeBio reported quarterly EPS of ($1.00), missing estimates by $0.25 while revenue of $154.2M beat expectations and rose 2,521% year-over-year, and analysts maintain a consensus "Moderate Buy" rating with an average price target of $87.71.

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CAO Maricel Apuli sold 2,000 shares of the company's stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $71.58, for a total transaction of $143,160.00. Following the sale, the chief accounting officer owned 134,115 shares in the company, valued at $9,599,951.70. The trade was a 1.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maricel Apuli also recently made the following trade(s):

• On Tuesday, February 17th, Maricel Apuli sold 510 shares of BridgeBio Pharma stock. The stock was sold at an average price of $74.31, for a total transaction of $37,898.10.

BridgeBio Pharma Price Performance

Shares of BBIO stock traded up $0.43 during trading hours on Monday, reaching $68.99. 1,886,949 shares of the stock were exchanged, compared to its average volume of 2,751,298. The business's fifty day moving average is $71.28 and its two-hundred day moving average is $71.05. BridgeBio Pharma, Inc. has a 12-month low of $31.77 and a 12-month high of $84.94. The firm has a market capitalization of $13.51 billion, a P/E ratio of -18.25 and a beta of 1.02.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last released its earnings results on Tuesday, February 24th. The company reported ($1.00) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.25). The company had revenue of $154.18 million for the quarter, compared to analysts' expectations of $150.71 million. During the same quarter last year, the firm earned ($1.40) EPS. The business's revenue for the quarter was up 2521.2% on a year-over-year basis. As a group, equities research analysts predict that BridgeBio Pharma, Inc. will post -2.05 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on BBIO shares. Morgan Stanley upped their target price on shares of BridgeBio Pharma from $96.00 to $98.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 25th. Raymond James Financial set a $89.00 target price on shares of BridgeBio Pharma and gave the stock an "outperform" rating in a research note on Thursday, February 12th. Oppenheimer cut their target price on shares of BridgeBio Pharma from $83.00 to $81.00 and set an "outperform" rating on the stock in a research note on Wednesday, February 25th. Leerink Partners restated an "outperform" rating and set a $98.00 target price on shares of BridgeBio Pharma in a research note on Thursday, March 12th. Finally, Royal Bank Of Canada began coverage on shares of BridgeBio Pharma in a research note on Thursday, April 9th. They issued an "outperform" rating and a $100.00 price target on the stock. Twenty-four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $87.71.

Hedge Funds Weigh In On BridgeBio Pharma

Several hedge funds have recently added to or reduced their stakes in the stock. Strs Ohio increased its stake in BridgeBio Pharma by 1.1% in the third quarter. Strs Ohio now owns 18,600 shares of the company's stock valued at $966,000 after purchasing an additional 200 shares during the last quarter. Commonwealth Equity Services LLC increased its stake in BridgeBio Pharma by 4.9% in the fourth quarter. Commonwealth Equity Services LLC now owns 5,179 shares of the company's stock valued at $396,000 after purchasing an additional 244 shares during the last quarter. Farther Finance Advisors LLC increased its stake in BridgeBio Pharma by 91.4% in the fourth quarter. Farther Finance Advisors LLC now owns 513 shares of the company's stock valued at $39,000 after purchasing an additional 245 shares during the last quarter. State of New Jersey Common Pension Fund D increased its stake in BridgeBio Pharma by 0.5% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 51,896 shares of the company's stock valued at $3,970,000 after purchasing an additional 246 shares during the last quarter. Finally, CWM LLC increased its stake in BridgeBio Pharma by 4.3% in the fourth quarter. CWM LLC now owns 6,444 shares of the company's stock valued at $493,000 after purchasing an additional 265 shares during the last quarter. 99.85% of the stock is currently owned by hedge funds and other institutional investors.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio's pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.